years, hampering revenue. The acquisition of Wyeth will produce cost savings and growth as will the purchase of King Pharmaceuticals, a pending $3.3 billion buyout announced in October, as many of Pfizer's top drugs lose revenue to generics. Pfizer...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to This Dow Dividend Stock Could Rise 51%
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account